Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012485 | 0.88 | ADRB3 (0.39) | ADRB2CASRADRB1MTNR1AMTNR1B | |
| SCHEMBL4012539 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL11747826 | 0.80 | ADRB2 (0.59) | ADRB2ADRB1CCR5LMNA | |
| SCHEMBL4019661 | 0.80 | ADRB2 (0.43) | ADRB2CASRADRB1MTNR1AMTNR1B | |
| SCHEMBL4022392 | 0.79 | ADRB2 (0.42) | ADRB2CASRADRB1MTNR1AMTNR1B | |
| SCHEMBL4014708 | 0.77 | ADRB2 (0.50) | ADRB2ADRB1CCR5LMNA | |
| SCHEMBL4014681 | 0.77 | ADRB2 (0.48) | ADRB2ADRB1CCR5LMNA | |
| SCHEMBL10634796 | 0.76 | ADRB2 (0.47) | ADRB2ADRB1CCR5 | |
| Acetic Acid SCHEMBL4013680 | 0.75 | ADRB2 (0.47) | ADRB2ADRB1CCR5LMNA | |
| SCHEMBL12158787 | 0.74 | ADRB2 (0.58) | ADRB2ADRB1CCR5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511067-B2 | 3-hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOUYSSOU THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1706389-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005066140-A1 | 3-HYDROXYMETHYL-4-HYDROXY-PHENYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234112-A1 | 3-Hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases | PAH, CYP11B1, CYP11B2 | ADRB2 117/4885CASR 4859/4885ADRB1 69/4885 |
| US-20080132556-A1 | 3-HYDROXYMETHYL-4HYDROXY-PHENYL- DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | PAH, CYP1A1, CYP11B1 | ADRB2 169/4885CASR 4859/4885ADRB1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.